Why Congo's Bundibugyo Ebola outbreak has no vaccine, when other Ebola does

There is no licensed vaccine and no approved treatment for Bundibugyo virus, the pathogen behind an Ebola outbreak that WHO reports has caused at least 3,269 deaths, all but two of them in the Democratic Republic of the Congo [s1]. The vaccines and antibody drugs credited with cutting Ebola's death rate over the past decade were developed against a different species, Zaire ebolavirus, and none is approved against the Bundibugyo virus now circulating [s2].

WHO's 10 September Disease Outbreak News put the cumulative total at 6,778 confirmed cases as of 7 September, of which 6,757 were in the DRC, 20 in Uganda and one in France, with two DRC-diagnosed patients treated in Germany [s1]. Within the DRC, 3,267 deaths give a crude case fatality ratio of 48.3%, and confirmed cases have been reported from 61 health zones across six provinces, with Ituri the worst affected — 28 of its 36 health zones have recorded cases [s1]. Since the previous update on 28 August, the country added 963 confirmed cases and 481 deaths, a rise WHO attributes partly to stronger surveillance and data reconciliation but also to sustained community transmission and geographic spread [s1]. WHO calls it the largest Ebola disease outbreak ever recorded in the DRC, of any species, and only the second caused by Bundibugyo virus in the country after 2012 [s1].

One genus, several species, uneven defences

"Ebola" names a group of related viruses, not a single one. Three of them — Ebola virus (the Zaire species), Sudan virus and Bundibugyo virus — are known to cause large outbreaks [s2]. The distinction is not academic, because the countermeasures stockpiled for Ebola emergencies are species-specific. Two vaccines are approved for Ebola virus disease caused by the Zaire species — Merck's Ervebo and Janssen's two-component Zabdeno and Mvabea — and WHO recommends Ervebo as part of outbreak response [s2]. For treatment, WHO strongly recommends two monoclonal antibodies, ansuvimab (mAb114) and Inmazeb (REGN-EB3), again against the Zaire species [s2]. For the other Ebola diseases, including those caused by Sudan and Bundibugyo viruses, there are no approved vaccines or therapeutics; candidate products are in development, and a core clinical-trial protocol exists to test them during outbreaks [s2].

That leaves the DRC response reliant on tools that predate the vaccine era: rapid case identification, isolation and supportive care, contact tracing, safe and dignified burials, and community engagement [s1]. Bundibugyo virus is zoonotic — fruit bats are the suspected reservoir — and spreads person to person through contact with the blood, secretions or other bodily fluids of infected people, or with contaminated surfaces, with transmission amplified in health-care settings that lack infection control and by unsafe burials [s1]. The incubation period runs from two to 21 days, and people are not infectious before symptoms begin, which is what makes contact tracing and prompt isolation effective when they can be sustained [s1].

Diagnosis is its own obstacle. Early Bundibugyo symptoms — fever, fatigue, muscle pain, headache and sore throat — are non-specific and hard to distinguish from malaria and other endemic febrile illnesses, so laboratory confirmation by PCR or antigen- and antibody-based assays is needed to separate cases, a step WHO says complicates clinical diagnosis and can delay detection [s1].

A lethal virus, roughly in line with its history

Bundibugyo virus is somewhat less lethal on paper than the Zaire species, whose outbreaks have historically killed an average of about half of those infected, in a range from 25% to 90% [s2]. But "less lethal" is relative. The current DRC outbreak's crude case fatality ratio of 48.3% sits between the ratios recorded in the only two previous Bundibugyo outbreaks: 30% when the virus was first identified in Uganda in 2007, and 50% in the DRC in 2012 [s1]. Case fatality in an ongoing outbreak is provisional — it shifts as cases and deaths are reconciled — but a ratio near one in two, with no specific drug to change the odds, is why WHO continues to treat the epidemic as a regional emergency [s1].

Whether that picture changes depends partly on the research pipeline. WHO says candidate vaccines and therapeutics for the non-Zaire Ebola species are under development, and its core protocol is designed so that any product deployed during this outbreak could generate usable trial data [s2]. Until one is approved, the arithmetic of the response is unforgiving: every additional health zone that reports cases, and every informal border crossing WHO flags as a route for onward spread, has to be met with the century-old fundamentals of outbreak control rather than a shot [s1]. The outbreak's continued growth across six provinces suggests those fundamentals are, for now, being outpaced [s1].

This article is informational and is not medical advice.

Sources

• [s1] World Health Organization, "Ebola disease caused by Bundibugyo virus — Democratic Republic of the Congo," Disease Outbreak News 2026-DON617, 10 September 2026. https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON617
• [s2] World Health Organization, "Ebola virus disease" fact sheet. https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease